Adverse Events in Trial Assessing Dara-KRd in Patients With Newly Diagnosed Multiple Myeloma

Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses the adverse events experienced by patients with newly diagnosed multiple myeloma who were administered daratumumab, carfilzomib, lenalidomide, and dexamethasone.

Pharmacy Times interviewed Luciano Costa, MD, PhD, associate director for clinical research at the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, on his recent presentation at the American Society of Hematology Annual Meeting and Exposition 2021 on the trial assessing daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous transplantation, and minimal residual disease response-adapted consolidation and treatment cessation.

During this video, Costa discusses the adverse events experienced by patients with newly diagnosed multiple myeloma who were administered Dara-KRd during the trial.

Related Content:

Multiple MyelomaOncologyHospitalSpecialty Pharmacy
Among Patients with Type 1 Diabetes, Woman May Be Less Likely Than Men to Receive Cardioprotective Medication for Cardiovascular Disease
Grant Awarded to Study Some of the Most Fatal Forms of Cancers
Researchers Are Developing Bispecific CAR Proteins to “Wake Up” the Immune Systems of Cancer Patients